Interpretation of Lipid Management in Patients with Endocrine Disorders：an Endocrine Society Clinical Practice Guideline Issued by The Endocrine Society in 2020

doi:10.12114/j.issn.1007-9572.2021.00.508

Abstract

Abstract: In recent years，China and many other countries have issued guidelines on lipid management for endocrine disease patients，indicating that lipid management is a very important section in endocrine disease treatment.However，most of previous guidelines only focused on managing lipids in patients with only one endocrine disease，with no systematic elaboration of lipid management in patients with multiple endocrine diseases.The Lipid Management in Patients with Endocrine Disorders：an Endocrine Society Clinical Practice Guideline issued by The Endocrine Society in 2020，is a guideline detailedly elaborates lipid management in patients with endocrine diseases for the first time，which will significantly contribute to lipid management in Chinese patients with endocrine diseases.For this reason，we interpreted the main points of this guideline.

Key words: Endocrine system diseases, Dyslipidemias, Cardiovascular diseases, Atherosclerosis, Guidebook, Hypertriglyceridemia, Diabetes mellitus, Obesity management, Thyroid diseases, Cushing syndrome, Growth hormone, Polycystic ovary syndrome, Hormones

摘要： 近年来，包括中国在内的多个国家相继发布了内分泌疾病患者血脂管理相关指南，体现出血脂管理是内分泌疾病患者治疗中一个相当重要的“版块”，但多数指南只是针对单一内分泌疾病，并没有针对内分泌疾病患者血脂异常进行综合阐述。2020年美国内分泌协会发布的《临床实践指南：内分泌疾病患者的血脂管理》首次针对内分泌疾病患者血脂异常进行了详细阐述，对我国内分泌疾病合并血脂异常患者的管理具有重要指导意义，本文对该指南主要内容进行了解读。

关键词: 内分泌系统疾病, 血脂异常, 心血管疾病, 动脉粥样硬化, 指南, 高甘油三酯血症, 糖尿病, 肥胖管理, 甲状腺疾病, 库欣综合征, 生长激素, 多囊卵巢综合征, 激素类

DENG Chenqian,CHEN Shuchun. Interpretation of Lipid Management in Patients with Endocrine Disorders：an Endocrine Society Clinical Practice Guideline Issued by The Endocrine Society in 2020　[J]. Chinese General Practice, 2021, 24(21): 2646-2654. DOI: 10.12114/j.issn.1007-9572.2021.00.508.
邓臣前,陈树春. 2020年美国内分泌协会《临床实践指南：内分泌疾病患者的血脂管理》解读[J]. 中国全科医学, 2021, 24(21): 2646-2654. DOI: 10.12114/j.issn.1007-9572.2021.00.508.

References

［1］NEWMAN C B，BLAHA M J，BOORD J B，et al．Lipid Management in Patients with Endocrine Disorders：An Endocrine Society Clinical Practice Guideline［J］．J Clin Endocrinol Metab，2020，105（12）：dgaa674．DOI：10.1210/clinem/dgaa674.
［2］热那提?肉孜，吴娜琼，孙荻，等．脂蛋白α水平与冠心病发生及严重程度的相关性探究［J］．中国心血管病研究，2020，18（3）：206-211．DOI：10.3969/j.issn.1672-5301.2020.03.004.
［3］DORAN B，GUO Y，XU J，et al．Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality：insight from the National Health and Nutrition Examination Survey Ⅲ（NHANES-Ⅲ）［J］．Circulation，2014，130（7）：546-553．DOI：10.1161/CIRCULATIONAHA.114.010001.
［4］Emerging Risk Factors Collaboration，ANGELANTONIO E D，SARWAR N，et al．Major lipids，apolipoproteins，and risk of vascular disease［J］．JAMA，2009，302（18）：1993-2000．DOI：10.1001/jama.2009.1619.
［5］LIU H H，LI J J.Ageing and dyslipidemia：a review of the potential mechanisms［J］．Ageing Res Rev，2015，19（1）：43-52．DOI：10.1016 /j.arr.2014.12.001.
［6］沈德蕾，陈浩，赵超，等．上海市徐汇区45~55岁居民动脉粥样硬化性心血管疾病风险的影响因素分析［J］．中国全科医学，2020，23（6）：716-720．DOI：10.12114/j.issn.1007-9572.2020.00.099.
［7］BUDOFF M J，YOUNG R，BURKE G，et al．Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease（ASCVD）events：the multi-ethnic study of atherosclerosis（MESA）［J］．Eur Heart J，2018，39（25）：2401-2408．DOI：10.1093/eurheartj/ehy217.
［8］TSIMIKAS S，FAZIO S，FERDINAND K C，et al．NHLBI Working Group recommendations to reduce lipoprotein（a）-mediated risk of cardiovascular disease and aortic stenosis［J］．J Am Coll Cardiol，2018，71（2）：177-192．DOI：10.1016/j.jacc，2017.11.014.
［9］SCHMIDT K，NOUREEN A，KRONENBERG F，et al．Structure，function，and genetics of lipoprotein（a）［J］．J Lipid Res，2016，57（8）：1339-1359．DOI：10.1194/jlr.R067314.
［10］CAO Y X，LIU H H，SUN D，et al．The different relations of PCSK9 and Lp（a）to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia［J］．Atherosclerosis，2018，277：7-14．DOI：10.1016/j.atherosclerosis.2018.07.030.
［11］MURPHY M J，SHENG X，MACDONALD T M，et al．Hypertriglyceridemia and acute pancreatitis［J］．JAMA Intern Med，2013，173（2）：162-164．DOI：10.1001/2013.jamainternmed.477.
［12］ZHANG X L，LI F，ZHEN Y M，et al．Clinical study of 224 patients with hypertriglyceridemia pancreatitis［J］．Chin Med J（Engl），2015，128（15）：2045-2049．DOI：10.4103/0366-6999.161361.
［13］KARALIS D G.A review of clinical practice guidelines for the management of hypertriglyceridemia：a focus on high dose omega-3 fatty acids［J］．Adv Ther 2017，34（2）：300-323．DOI：10.1007/s12325-016-0462-y.
［14］KIDO K，EVANS R A，GOPINATH A，et al．Severe hypertriglyceridemia induced by sirolimus treated with medical management without plasmapheresis：a case report［J］．J Pharm Pract，2018，31（1）：104-106．DOI：10.1177/0897190017692920.
［15］廖丽芳，杨柏炜，何志云.血浆置换在糖尿病合并轻中型急性高脂血症型胰腺炎中治疗的作用［J］．中外医学研究，2015，13（26）：44-45．DOI：10.14033/j.cnki.cfmr.2015.26.022.
［16］BRAHM A J，HEGELE R A.Chylomicronaemia——current diagnosis and future therapies［J］．Nat Rev Endocrinol，2015，11（6）：352-362．DOI：10.1038/nrendo.2015.26.
［17］CHEN J H，YEH J H，LAI H W，et al．Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis［J］．World J Gastroenterol，2004，10（15）：2272-2274．DOI：10.3748/wjg.v10.i15.2272.
［18］BHATT D L，STEG P G，MILLER M，et al．Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia［J］．N Engl J Med，2019，380（1）：11-22．DOI：10.1056/NEJMoa1812792.
［19］HANSEN M，SONNE D P，MIKKELSEN K H，et al．Bile acid sequestrants for glycemic control in patients with type 2 diabetes：a systematic review with meta-analysis of randomized controlled trials［J］．J Diabetes Complications，2017，31（5）：918-927．DOI：10.1016/j.jdiacomp.2017.01.011.
［20］SABATINE M S，GIUGLIANO R P，KEECH A C，et al．Evolocumab and clinical outcomes in patients with cardiovascular disease［J］．N Engl J Med，2017，376（18）：1713-1722．DOI：10.1056/NEJMoa1615664.
［21］KEECH A，SIMES R J，BARTER P，et al．Effects of long-term fenofibrate therapy on cardiovas cular events in 9795 people with type 2 diabetes mellitus（the FIELD study）：randomised controlled trial［J］．Lancet，2005，366（9500）：1849-1861．DOI：10.1016/S0140-6736（05）67667-2.
［22］MORGAN C L，OWENS D R，AUBONNET P，et al．Primary prevention of diabetic retinopathy with fibrates：a retrospective，matched cohort study［J］．BMJ Open，2013，3（12）：e004025．DOI：10.1136/bmjopen-2013-004025.
［23］RAWSHANI A，SATTAR N，FRANZéN S，et al．Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset：a nationwide，register-based cohort study［J］．Lancet，2018，392（10146）：477-486．DOI：10.1016/S0140-6736（18）31506-X.
［24］KRAMER C K，RODRIGUES T C，CANANI L H，et al．Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes：meta-analysis of observational studies［J］．Diabetes Care，2011，34（5）：1238-1244．DOI：10.2337/dc11-0079.
［25］MACH F，BAIGENT C，CATAPANO A L，et al．2019 ESC/EAS guidelines for the management of dyslipidaemias：lipid modification to reduce cardiovascular risk［J］．Eur Heart J，2020，41（1）：111-188．DOI：10.1093/eurheartj/ehz455.
［26］JUNG K Y，AHN H Y，HAN S K，et al．Association between thyroid function and lipid profiles，apolipoproteins，and high-density lipoprotein function［J］．J Clin Lipidol，2017，11（6）：1347-1353．DOI：10.1016/j.jacl.2017.08.015.
［27］RAZVI S，JABBAR A，PINGITORE A，et al．Thyroid hormones and cardiovascular function and diseases［J］．J Am Coll Cardiol，2018，71（16）：1781-1796．DOI：10.1016/j.jacc.2018.02.045.
［28］HEIMBERG M，OLUBADEWO J O，WILCOX H G.Plasma lipoproteins and regulation of hepatic metabolism of fatty acids in altered thyroid states［J］．Endocr Rev，1985，6（4）：590-607．DOI：10.1210/edrv-6-4-590.
［29］KYRIACOU A，KYRIACOU A，MAKRIS K C，et al．Weight gain following treatment of hyperthyroidism——a forgotten tale［J］．Clin Obes，2019，9（5）：e12328．DOI：10.1111/cob.12328.
［30］TORLINSKA B，NICHOLS L，MOHAMMED M A，et al．Patients treated for hyperthyroidism are at increased risk of becoming obese：findings from a large prospective secondary care cohort［J］．Thyroid，2019，29（10）：1380-1389．DOI：10.1089/thy.2018.0731.
［31］GIORDANO R，PICU A，MARINAZZO E，et al．Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission［J］．Clin Endocrinol（Oxf），2011，75（3）：354-360．DOI：10.1111/j.1365-2265.2011.04055.x.
［32］CHRIST E R，CUMMINGS M H，JACKSON N，et al．Effects of growth hormone（GH）replacement therapy on low-density lipoprotein apolipoprotein B100 kinetics in adult patients with GH deficiency：a stable isotope study［J］．J Clin Endocrinol Metab，2004，89（4）：1801-1807．DOI：10.1210/jc.2003-031474.
［33］DI SOMMA C，SCARANO E，SAVASTANO S，et al．Cardiovascular alterations in adult GH deficiency［J］．Best Pract Res Clin Endocrinol Metab，2017，31（1）：25-34．DOI：10.1016/j.beem.2017.03.005.
［34］SHERLOCK M，AYUK J，TOMLINSON J W，et al．Mortality in patients with pituitary disease［J］．Endocr Rev，2010，31（3）：301-342．DOI：10.1210/er.2009-0033.
［35］SCHMIDT J，LANDIN-WILHELMSEN K，BR?NNSTR?M M，et al．Cardiovascular disease and risk factors in PCOS women of postmenopausal age：a 21-year controlled follow-up study［J］．J Clin Endocrinol Metab，2011，96（12）：3794-3803．DOI：10.1210/jc.2011-1677.
［36］LEGRO R S，ARSLANIAN S A，EHRMANN D A，et al．Diagnosis and treatment of polycystic ovary syndrome：an Endocrine Society clinical practice guideline［J］．J Clin Endocrinol Metab，2013，98（12）：4565-4592．DOI：10.1210/jc.2013-2350.
［37］PUURUNEN J，PILTONEN T，PUUKKA K，et al．Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome（PCOS）：a prospective，randomized，double-blind，placebo-controlled study［J］．J Clin Endocrinol Metab，2013，98（12）：4798-4807．DOI：10.1210/jc.2013-2674.
［38］SATHYAPALAN T，SMITH K A，COADY A M，et al．Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome：randomized controlled study［J］．Ann Clin Biochem，2012，49（Pt 1）：80-85．DOI：10.1258/acb.2011.011071.
［39］GHAZEERI G，ABBAS H A，SKAFF B，et al．Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients［J］．J Endocrinol Invest，2015，38（6）：643-651．DOI：10.1007/s40618-015-0237-3.
［40］PALMISANO B T，ZHU L，STAFFORD J M.Role of estrogens in the regulation of liver lipid metabolism［J］．Adv Exp Med Biol，2017，1043：227-256．DOI：10.1007/978-3-319-70178-3_12.
［41］TETSCHE M S，JACOBSEN J，N?RGAARD M，et al．Postmenopausal hormone replacement therapy and risk of acute pancreatitis：a population-based case-control study［J］．Am J Gastroenterol，2007，102（2）：275-278．DOI：10.1111/j.1572-0241.2006.00924.x.
［42］ALJENEDIL S，HEGELE R A，GENEST J，et al．Estrogen-associated severe hypertriglyceridemia with pancreatitis［J］．J Clin Lipidol，2017，11（1）：297-300．DOI：10.1016/j.jacl.2016.12.006.
［43］GOLDENBERG N M，WANG P，GLUECK C J.An observational study of severe hypertriglyceridemia，hypertriglyceridemic acute pancreatitis，and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia［J］．Clin Chim Acta，2003，332（1/2）：11-19．DOI：10.1016/s0009-8981（03）00129-3.
［44］MANSON J E，CHLEBOWSKI R T，STEFANICK M L，et al．Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials［J］．JAMA，2013，310（13）：1353-1368．DOI：10.1001/jama.2013.278040.
［45］SALPETER S R，WALSH J M，GREYBER E，et al．Brief report：coronary heart disease events associated with hormone therapy in younger and older women.A meta-analysis［J］．J Gen Intern Med，2006，21（4）：363-366．DOI：10.1111/j.1525-1497.2006.00389.x.
［46］FOURNIER J P，DUIJNHOVEN R G，RENOUX C，et al．Concurrent use of statins and hormone therapy and risk of venous thromboembolism in postmenopausal women：a population-based case-control study［J］．Menopause，2014，21（9）：1023-1026．DOI：10.1097/GME.0000000000000279.
［47］DANAEI G，TAVAKKOLI M，HERNáN M A.Bias in observational studies of prevalent users：lessons for comparative effectiveness research from a meta-analysis of statins［J］．Am J Epidemiol，2012，175（4）：250-262．DOI：10.1093/aje/kwr301.
［48］JONES T H，ARVER S，BEHRE H M，et al．Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome（the TIMES2 study）［J］．Diabetes Care，2011，34（4）：828-837．DOI：10.2337/dc10-1233.
［49］PASTUSZAK A W，GOMEZ L P，SCOVELL J M，et al．Comparison of the effects of testosterone gels，injections，and pellets on serum hormones，erythrocytosis，lipids，and prostate-specific antigen［J］．Sex Med，2015，3（3）：165-173．DOI：10.1002/sm2.76.
［50］SNYDER P J，BHASIN S，CUNNINGHAM G R，et al．Effects of testosterone treatment in older men［J］．N Engl J Med，2016，374（7）：611-624．DOI：10.1056/NEJMoa1506119.
［51］IRWIG M S.Testosterone therapy for transgender men［J］．Lancet Diabetes Endocrinol，2017，5（4）：301-311．DOI：10.1016/S2213-8587（16）00036-X.
［52］MARAKA S，SINGH OSPINA N，RODRIGUEZ-GUTIERREZ R，et al．Sex steroids and cardiovascular outcomes in transgender individuals：a systematic review and meta-analysis［J］．J Clin Endocrinol Metab，2017，102（11）：3914-3923．DOI：10.1210/jc.2017-01643.

[1]	ZHANG Peng, LIU Lidi, ZHANG Ying, YANG Ziyu, LIU Changming, TANG Yijun, LIAO Xiaoyang, JIA Yu. Interpretation and Clinical Implications of the 2024 Italian Guidelines for the Management of Adult Individuals with Overweight and Obesity and Metabolic Comorbidities That are Resistant to Behavioral Treatment [J]. Chinese General Practice, 2025, 28(30): 3747-3752.
[2]	ZHOU Sheng, DENG Changsheng, ZOU Guanyang, SONG Jianping. Research Progress on the Pathogenesis of Complications of Malaria in Cardiovascular Diseases [J]. Chinese General Practice, 2025, 28(27): 3466-3472.
[3]	XIANG Xinyue, ZHANG Bingqing, OUYANG Yuqin, TANG Wenjuan, FENG Wenhuan. Impact of Short-term Medical Weight Loss on Atherosclerotic Cardiovascular Disease Risk in Patients with Obesity [J]. Chinese General Practice, 2025, 28(26): 3229-3239.
[4]	ZHANG Ruimin, DONG Zheyi, LI Shuang, WANG Qian, CHEN Xiangmei. Traditional Chinese Medicine Factors Associated with Diabetic Nephropathy Diagnosed by Renal Biopsy [J]. Chinese General Practice, 2025, 28(26): 3307-3313.
[5]	ZHANG Yunuo, LI Ruibin, WANG Wei. Correlation Analysis of Serum Nesfatin-1 and Ghrelin Levels with Glycolipid Metabolism and Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2025, 28(26): 3264-3270.
[6]	TANG Shangfeng, HUANG Yangzhen, ZHENG Yanxi, PAN Yangyang, XIONG Zhongbao, QING Hua, SONG Jia, WEI Yilin, DONG Heng, WANG Chunying, CHEN Manwei, ZHANG Kangkang. Specification for the Integration of Healthcare and Prevention Services in Diabetes at the Primary Level [J]. Chinese General Practice, 2025, 28(25): 3096-3103.
[7]	LIU Yinyin, SUI Hongping, LI Tingting, JIANG Tongtong, SHI Tieying, XIA Yunlong. Advances in Risk Prediction Models for Cardiotoxicity Associated with Breast Cancer Treatment [J]. Chinese General Practice, 2025, 28(24): 3072-3078.
[8]	YANG Chen, CHEN Tong, ZHANG Lifang, ZHANG Hongxu, LI Pengfei, ZHANG Xuejuan. Prognostic Impact of Dapagliflozin in Elderly Breast Cancer Survivors with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes [J]. Chinese General Practice, 2025, 28(24): 3053-3058.
[9]	WANG Rupeng, NAN Jing, HU Yiran, YANG Shenghua, JIN Zening. Predictive Value of the Triglyceride-Glucose Body Mass Index for Slow Flow/No-reflow Phenomenon in Patients with Type 2 Diabetes Mellitus and Acute Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention [J]. Chinese General Practice, 2025, 28(24): 2985-2992.
[10]	LIU Yueying, WANG Xueli, LIU Yuqiu, WEI Limin. Correlation of Fasting C-peptide to Diabetes Duration Ration and Type 2 Diabetes Mellitus Combined with Metabolism-related Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2852-2860.
[11]	BAI Xue, CHEN Qianqian, LI Jie. Innovative Practices in Chronic Disease Management: a New Model for Generalist-Specialist Combination Management of Diabetes and Metabolic Dysfunction-associated Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2841-2845.
[12]	WANG Peng, QIU Lixia, XU Shanshan, ZHANG Yang, ZHANG Jing, DU Xiaofei. Advances in the Co-management of Metabolism Dysfunction-associated Fatty Liver Disease and Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2025, 28(23): 2846-2851.
[13]	GAO Haijun, REN Jiayu, WANG Ruolin, ZHOU Huiya, QU Peng. Research Progress on the Role of Endothelial Cell Injury and Dysfunction in Atherosclerosis [J]. Chinese General Practice, 2025, 28(21): 2697-2704.
[14]	WANG Ying, YAN Yijun, LIU Lei, HU Yumin, ZHANG Yang, LIU Kai, JIANG Boren. Effects of Resistance Exercise Combined with Nutritional Intervention on Blood Glucose Stability in Elderly Patients with Type 2 Diabetes Mellitus with Sarcopenia [J]. Chinese General Practice, 2025, 28(21): 2604-2610.
[15]	JIN Yan, YANG Yang, WANG Lulu, ZHENG Qingwan, LI Xinyan, ZHANG Ning. Effects of Exercise Training after Bariatric Surgery on Cardiopulmonary Function in Patients with Type 2 Diabetes Mellitus and Obesity: a Randomized Controlled Trial [J]. Chinese General Practice, 2025, 28(21): 2611-2617.